Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Receivables (2016 - 2019)

Historic Receivables for Theravance Biopharma (TBPH) over the last 7 years, with Q3 2019 value amounting to $20.1 million.

  • Theravance Biopharma's Receivables rose 18981.39% to $20.1 million in Q3 2019 from the same period last year, while for Sep 2019 it was $20.1 million, marking a year-over-year increase of 18981.39%. This contributed to the annual value of $10.7 million for FY2018, which is 1400.34% up from last year.
  • Latest data reveals that Theravance Biopharma reported Receivables of $20.1 million as of Q3 2019, which was up 18981.39% from $20.1 million recorded in Q2 2019.
  • Over the past 5 years, Theravance Biopharma's Receivables peaked at $39.1 million during Q1 2016, and registered a low of $4.8 million during Q1 2018.
  • Over the past 5 years, Theravance Biopharma's median Receivables value was $13.1 million (recorded in 2017), while the average stood at $17.3 million.
  • In the last 5 years, Theravance Biopharma's Receivables surged by 67406666.67% in 2015 and then plummeted by 8195.8% in 2017.
  • Quarter analysis of 5 years shows Theravance Biopharma's Receivables stood at $37.2 million in 2015, then tumbled by 73.83% to $9.7 million in 2016, then dropped by 3.7% to $9.4 million in 2017, then grew by 14.0% to $10.7 million in 2018, then skyrocketed by 88.2% to $20.1 million in 2019.
  • Its Receivables was $20.1 million in Q3 2019, compared to $20.1 million in Q2 2019 and $7.9 million in Q1 2019.